Randomised clinical trial: L-ornithine-l-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 1, 2014, Pages 63-71

  Bai, M ^a   He, C ^a   Yin, Z ^a   Niu, J ^a   Wang, Z ^a   Qi, X ^a   Liu, L ^a   Yang, Z ^a   Guo, W ^a   Tie, J ^a   Bai, W ^a   Xia, J ^b   Cai, H ^b   Wang, J ^a   Wu, K ^a   Fan, D ^a   Han, G ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; ORNITHINE ASPARTATE;

ABDOMINAL PAIN; ADULT; AMMONIA BLOOD LEVEL; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIET RESTRICTION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FUNCTIONAL ASSESSMENT; HEPATIC ENCEPHALOPATHY; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; NEUROPROTECTION; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;

ADULT; AMMONIA; DIPEPTIDES; FEMALE; HEPATIC ENCEPHALOPATHY; HUMANS; KIDNEY FUNCTION TESTS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; POSTPRANDIAL PERIOD; PSYCHOMETRICS; TREATMENT OUTCOME;

EID: 84902204300     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12795     Document Type: Article

References (40)

1. Boyer TD, Haskal ZJ,. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005; 41: 386-400.
2. Boyer TD, Haskal ZJ,. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology 2010; 51: 306.
3. de Franchis R,. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53: 762-8.
4. Poordad FF,. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 2007; 25 (Suppl. 1): 3-9.
5. Riggio O, Ridola L, Pasquale C, et al,. Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy. Clin Gastroenterol Hepatol 2011; 9: 181-3.
6. Bajaj JS, Schubert CM, Heuman DM, et al,. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology 2010; 138: 2332-40.
7. Chen HJ, Jiao Y, Zhu XQ, et al,. Brain dysfunction primarily related to previous overt hepatic encephalopathy compared with minimal hepatic encephalopathy: resting-state functional MR imaging demonstration. Radiology 2013; 266: 261-70.
8. Bai M, Han GH, Yuan SS, et al,. Early hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: the risk factors and long-time survival. Zhonghua Gan Zang Bing Za Zhi 2011; 19: 498-501.
9. Riggio O, Masini A, Efrati C, et al,. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol 2005; 42: 674-9.
10. Haussinger D, Schliess F,. Pathogenetic mechanisms of hepatic encephalopathy. Gut 2008; 57: 1156-65.
11. Prakash R, Mullen KD,. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 2010; 7: 515-25.
12. Ong JP, Aggarwal A, Krieger D, et al,. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003; 114: 188-93.
13. Riggio O, Merlli M, Pedretti G, et al,. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors. Dig Dis Sci 1996; 41: 578-84.
14. Nolte W, Wiltfang J, Schindler C, et al,. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psycho-metric, and electroencephalographic investigations. Hepatology 1998; 28: 1215-25.
15. Riggio O, Ridola L, Angeloni S, et al,. Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial. J Hepatol 2010; 53: 267-72.
16. Cash WJ, McConville P, McDermott E, McCormick PA, Callender ME, McDougall NI,. Current concepts in the assessment and treatment of hepatic encephalopathy. QJM 2010; 103: 9-16.
17. Rose C, Michalak A, Rao KV, Quack G, Kircheis G, Butterworth RF,. L-ornithine-L-aspartate lowers plasma and cerebro-spinal fluid ammonia and prevents brain edema in rats with acute liver failure. Hepatology 1999; 30: 636-40.
18. Stauch S, Kircheis G, Adler G, et al,. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 1998; 28: 856-64.
19. Rose C, Michalak A, Pannunzio P, et al,. L-ornithine-L-aspartate in experi-mental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action. Metab Brain Dis 1998; 13: 147-57.
20. Staedt U, Leweling H, Gladisch R, Kortsik C, Hagmuller E, Holm E,. Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design. J Hepatol 1993; 19: 424-30.
21. Bai M, Yang Z, Qi X, Fan D, Han G,. L-ornithine-L-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2013; 28: 783-92.
22. Kircheis G, Nilius R, Held C, et al,. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997; 25: 1351-60.
23. Mittal VV, Sharma BC, Sharma P, Sarin SK,. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2011; 23: 725-32.
24. Rossle M, Siegerstetter V, Olschewski M, Ochs A, Berger E, Haag K,. How much reduction in portal pressure is necessary to prevent variceal rebleeding? A longitudinal study in 225 patients with transjugular intrahepatic portosystemic shunts. Am J Gastroenterol 2001; 96: 3379-83.
25. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT,. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.
26. Rossle M, Deibert P, Haag K, et al,. Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet 1997; 349: 1043-9.
27. Mamiya Y, Kanazawa H, Kimura Y, et al,. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Hepatol Res 2004; 30: 162-8.
28. Schmid M, Peck-Radosavljevic M, Konig F, Mittermaier C, Gangl A, Ferenci P,. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis. Liver Int 2010; 30: 574-82.
29. Rees CJ, Oppong K, Al Mardini H, Hudson M, Record CO,. Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial. Gut 2000; 47: 571-4.
30. Haag K, Lu S, Rossle M, et al,. The influence of TIPS on portal haemodynamics and liver function with respect to hepatic encephalopathy and survival. Hepatology 1995; 22: 296A.
31. Rossle M, Haag K, Ochs A, et al,. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994; 330: 165-71.
32. Jalan R, Gooday R, O'Carroll RE, Redhead DN, Elton RA, Hayes PC,. A prospective evaluation of changes in neuropsychological and liver function tests following transjugular intrahepatic portosystemic stent-shunt. J Hepatol 1995; 23: 697-705.
33. Najmi AK, Pillai KK, Pal SN, Akhtar M, Aqil M, Sharma M,. Effect of L-ornithine L-aspartate against thioacetamide-induced hepatic damage in rats. Indian J Pharmacol 2010; 42: 384-7.
34. Grungreiff K, Lambert-Baumann J,. Efficacy of L-ornithin-L-aspartate- granules in chronic liver diseases. Medizinische Welt 2001; 52: 219-26.
35. Guevara M, Gines P, Bandi JC, et al,. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28: 416-22.
36. Anderson CL, Saad WE, Kalagher SD, et al,. Effect of transjugular intrahepatic portosystemic shunt placement on renal function: a 7-year, single-center experience. J Vasc Interv Radiol 2010; 21: 1370-6.
37. Saugel B, Phillip V, Gaa J, et al,. Advanced hemodynamic monitoring before and after transjugular intrahepatic portosystemic shunt: implications for selection of patients-a prospective study. Radiology 2012; 262: 343-52.
38. Somberg KA, Riegler JL, LaBerge JM, et al,. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. Am J Gastroenterol 1995; 90: 549-55.
39. Masson S, Mardini HA, Rose JD, Record CO,. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion: a decade of experience. QJM 2008; 101: 493-501.
40. Quero Guillen JC, Herrerias Gutierrez JM,. Diagnostic methods in hepatic encephalopathy. Clin Chim Acta 2006; 2: 1-8.